(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.12%.
Annovis Bio's earnings in 2026 is -$28,854,197.On average, 4 Wall Street analysts forecast ANVS's earnings for 2026 to be -$36,731,406, with the lowest ANVS earnings forecast at -$38,903,419, and the highest ANVS earnings forecast at -$33,941,249. On average, 4 Wall Street analysts forecast ANVS's earnings for 2027 to be -$38,177,525, with the lowest ANVS earnings forecast at -$37,791,893, and the highest ANVS earnings forecast at -$38,109,472.
In 2028, ANVS is forecast to generate -$52,494,097 in earnings, with the lowest earnings forecast at -$67,247,339 and the highest earnings forecast at -$36,025,360.